Urinary bladder cancer: biomarkers and target therapy, new era for more attention | Zendy

Amrallah A. Mohammed | Zendy; Hani El-Tanni | Zendy; Hani M. EL-Khatib | Zendy; Ahmad A. Mirza | Zendy; Abdulrahim A. Mirza | Zendy; Turki H Alturaifi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Urinary bladder cancer: biomarkers and target therapy, new era for more attention

Author(s) -

Amrallah A. Mohammed,

Hani El-Tanni,

Hani M. EL-Khatib,

Ahmad A. Mirza,

Abdulrahim A. Mirza,

Turki H Alturaifi

Publication year - 2016

Publication title -

oncology reviews

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.637

H-Index - 21

eISSN - 1970-5565

pISSN - 1970-5557

DOI - 10.4081/oncol.2016.320

Subject(s) - medicine , bladder cancer , molecular biomarkers , disease , cancer , tumor stage , urinary system , oncology , bioinformatics , biology

Currently, bladder cancer (BCa) evaluation depends mainly on traditional clinicopathological parameters encompassing tumor stage and grade, which will not reflect the behavior of the disease. Diverse molecular alterations are responsible for the heterogeneous course. The differences in molecular pathogenesis between non-invasive BCa and invasive BCa have been recognized. Molecular biomarkers are promising to predict progression and survival. The management of advanced BCa remains somewhat primitive in comparison with other more common malignancies. This topic will discuss the molecular pathways, biomarkers and potential targets that may improve the outcome in BCa

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research